Innovation and Clinical Trial Tracking Fact book 2017 | Pharmaceuticals Market Research Reports

WE ARE JSB Market Research
JSB Market Research Pvt. Ltd was formed in 2013 and the portal www.jsbmarketresearch.com for quality
primary market research reports was launched to dedicatedly provide quick search service to global
clients with no restriction to any industry verticals.

About Report
Iovatio ad Cliical Trial Trackig Fact book 2017: An Assessment of the
Pharaceutical Pipelie is a coprehesive, graular aalysis of the 25,522
products currently in the pharmaceutical industry pipeline, from the Discovery
stage through to Pre-registration and split into therapy areas and key indications.

Table of Content
Introduction.
Assessment of the Pharmaceutical Industry Pipeline.
Assessment of Innovation in the Pharmaceutical Industry Pipeline.
Assessment of the Pharmaceutical Industry Clinical Trial Landscape.
Appendix.

Key Reasons to Purchase
up-to-date understanding of the landscape of the overall pharmaceutical
pipeline.
Highly accessible reference which is useful in any pharmaceutical strategic
decision making process.
Benchmark key therapy areas and indications in terms of the number of
pipeline products and level of innovation

Summary
“Innovation and Clinical Trial Tracking Fact book 2017: An Assessment of
the Pharmaceutical Pipeline” is a comprehensive, granular analysis of the
25,522 products currently in the pharmaceutical industry pipeline, from
the Discovery stage through to Pre-registration and split into therapy
areas and key indications

Scope
What is the current size and composition of the pharmaceutical industry
pipeline and how has it changed in the last two years? What can we learn from
this?
- The largest therapy area, by a substantial margin, is oncology, and, with
growth in the pipeline sizes for all major oncology indications since Q1 2015,
this trend appears set to continue. Why is this the case?

Focus Of Report
A particular focus of this report is placed on analysis of the
development of innovative drugs, specifically first-in-class
innovation. The proportion of first-in-class approvals has
increased steadily each year since 1994, with the exception of
the years 2005–2008, when the proportion was relatively high.

Related Reports
Success Case Study: Green Giant "Swap-In" Frozen Vegetables - Frozen vegetable innovation
making healthy swaps easier
Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical
Pipeline
Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and
Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

We would be pleased to hear from you. Here you can find all important contacts.
CONTACT US
India, Maharashtra, Navi Mumbai.
support@jsbmarketresearch.com
www.jsbmarketresearch.com

Thank You
JSB Market Research is developing new possibilities.